Molar Pregnancy Treatment in India
Get Molar Pregnancy Treatment at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Molar Pregnancy Treatment in UAE
Molar Pregnancy Treatment at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Molar pregnancy, a rare but serious form of gestational trophoblastic disease (GTD), requires prompt diagnosis and expert management to prevent progression to malignant gestational trophoblastic neoplasia (GTN). With success rates exceeding 95% when treated early, international patients increasingly choose India and the UAE for their world-class gynecologic oncology teams, advanced suction curettage facilities, and rigorous post-treatment hCG surveillance protocols. GAF Healthcare connects patients to NABH- and JCI-accredited hospitals in India and JCI- and DHA-licensed centers in Dubai and Abu Dhabi, offering transparent pricing, end-to-end coordination, and specialist-led care at a fraction of Western costs.
Hospital Stay: 1–3 days (for primary evacuation procedure; longer if chemotherapy is initiated for malignant transformation) • Total Stay in Country (Fit-to-Fly): 2–4 weeks (following confirmed declining serum β-hCG trend and clearance by the treating gynecologic oncologist; up to 8–12 weeks if chemotherapy for GTN is required) • Success Rate: 95–99% (complete hydatidiform mole treated before malignant transformation; GTN treated with single-agent chemotherapy achieves ~98–100% cure rate in low-risk FIGO classification)
What Is It?
A molar pregnancy arises from an abnormal fertilization event that produces a non-viable, rapidly proliferating trophoblastic mass instead of a normal placenta and fetus. In a complete hydatidiform mole (CHM), a haploid sperm fertilizes an empty or enucleated ovum and duplicates, yielding a 46,XX (or rarely 46,XY) androgenetic diploid genome with no fetal tissue, diffuse hydropic villous change, and markedly elevated serum beta-human chorionic gonadotropin (β-hCG). A partial hydatidiform mole (PHM) results from dispermic fertilization of a normal ovum, producing a triploid genome (69,XXX or 69,XXY) with focal hydropic change, some fetal tissue remnants, and a more modest β-hCG elevation. Both subtypes are classified under gestational trophoblastic disease (GTD) and carry a risk of malignant transformation into gestational trophoblastic neoplasia (GTN), including invasive mole, choriocarcinoma, placental-site trophoblastic tumor (PSTT), or epithelioid trophoblastic tumor (ETT).
The physiological impact is substantial. Abnormal trophoblastic proliferation stimulates excessive β-hCG production, which in turn causes bilateral theca-lutein ovarian cysts (in up to 25–30% of CHM cases), hyperemesis, hyperthyroidism (due to structural homology between β-hCG and TSH), and an elevated risk of pre-eclampsia before 20 weeks. Uterine size is frequently large-for-dates, and spontaneous hemorrhage can precipitate hemodynamic instability. Rarely, trophoblastic pulmonary emboli cause acute respiratory distress. The placental-site trophoblastic tumor and ETT subtypes are notable for low β-hCG relative to their mass and are relatively resistant to standard chemotherapy regimens, requiring individualized management.
The internationally accepted standard of care follows the guidelines of FIGO (International Federation of Gynecology and Obstetrics), ESGO, and the Royal College of Obstetricians and Gynaecologists (RCOG). Initial management consists of ultrasound confirmation, baseline labs (complete β-hCG quantification, CBC, comprehensive metabolic panel, thyroid function tests, chest X-ray), and uterine evacuation via suction curettage under ultrasound guidance. Post-evacuation, a structured serial β-hCG surveillance protocol — typically weekly until normalization, then monthly for 6–12 months — determines whether the disease has resolved or progressed to GTN requiring chemotherapy. India's leading trophoblastic disease centers and UAE's oncology hubs operate formal GTD registers mirroring the Charing Cross model, ensuring no patient falls through surveillance gaps.
Candidates
• CONFIRMED DIAGNOSIS (eligible patients): Women of reproductive age diagnosed via pelvic ultrasound demonstrating the classic 'snowstorm' echogenic uterine pattern, combined with disproportionately elevated serum β-hCG (often >100,000 mIU/mL in CHM), and pathological confirmation via histology after uterine evacuation.
• PARTIAL MOLE CANDIDATES: Women with suspected PHM presenting with missed or incomplete miscarriage on ultrasound, lower β-hCG elevation, and triploid karyotype confirmed on products-of-conception (POC) histology with p57 immunohistochemistry and flow cytometry.
• POST-EVACUATION SURVEILLANCE CANDIDATES: Any patient with a prior diagnosis of GTD anywhere in the world who requires formal serial β-hCG follow-up, repeat imaging, or initiation/completion of chemotherapy for GTN.
• GTN / MALIGNANT TRANSFORMATION CANDIDATES: Patients meeting FIGO 2000 criteria for post-molar GTN — plateau or rise in β-hCG over three consecutive weekly measurements, histological diagnosis of choriocarcinoma, invasive mole, PSTT, or ETT, or evidence of metastatic disease on chest X-ray or CT thorax/abdomen/pelvis.
• REQUIRED DIAGNOSTIC WORKUP PRIOR TO TRAVEL:
• Serum β-hCG (quantitative, within 48–72 hours of consultation)
• Pelvic ultrasound with Doppler (assess vascularity and uterine size)
• Complete blood count, renal function, liver function, thyroid function (TSH, free T4)
• Blood group and antibody screen
• Chest X-ray (PA view) — mandatory baseline for GTN staging
• CT scan of chest, abdomen, and pelvis with contrast (if GTN suspected or β-hCG plateau/rise)
• MRI brain (if neurological symptoms or FIGO score ≥7 suggesting high-risk GTN)
• FIGO/WHO Prognostic Scoring System calculation (score 0–6 = low risk; score ≥7 = high risk GTN)
• RELATIVE CONTRAINDICATIONS / SPECIAL CONSIDERATIONS:
• Severe hemodynamic instability requiring resuscitation before transfer — patient must be stabilized locally before international travel
• Active, uncontrolled hyperthyroidism secondary to β-hCG stimulation (requires antithyroid therapy and beta-blockade prior to evacuation to prevent thyroid storm)
• Theca-lutein cysts >10 cm (increased hemorrhage risk; managed conservatively unless torsion occurs)
• PSTT or ETT with >4 years interval from antecedent pregnancy (associated with poor prognosis; requires multidisciplinary oncology review)
• Current pregnancy in the other uterine horn (extremely rare; specialist counseling required)
Procedure
STEP 1 — UTERINE EVACUATION (PRIMARY TREATMENT FOR HYDATIDIFORM MOLE):
Suction curettage (vacuum aspiration) under ultrasound guidance is the definitive first-line treatment for both CHM and PHM, regardless of uterine size. It is performed under general or regional anesthesia. A wide-bore (12–14 mm) suction cannula is used to evacuate the molar tissue, with real-time ultrasound monitoring to confirm complete evacuation and minimize perforation risk. Oxytocin infusion is commenced intraoperatively after cervical dilation (not before, to avoid trophoblast dissemination) and continued postoperatively. Sharp curettage as a second pass is no longer routinely recommended as it increases the risk of intrauterine adhesions (Asherman's syndrome) without improving outcomes. Intraoperative blood transfusion standby is mandatory given hemorrhage risk. For women who have completed childbearing and with confirmed CHM, hysterectomy is an alternative that eliminates the risk of local invasion, though it does not eliminate the need for β-hCG surveillance and does not prevent pulmonary or vaginal metastasis.
STEP 2 — PROPHYLACTIC CHEMOTHERAPY (SELECTIVE):
Routine prophylactic chemotherapy following molar evacuation is not universally recommended. However, it may be offered in high-risk CHM settings where reliable β-hCG surveillance is impossible (e.g., in regions with no laboratory access). A single course of Methotrexate (MTX) 50 mg/m² IM or Actinomycin-D (Act-D) is used. Leading Indian and UAE centers follow FIGO and ESMO guidelines strictly, offering this only when surveillance access is genuinely compromised.
STEP 3 — CHEMOTHERAPY FOR LOW-RISK GTN (FIGO SCORE 0–6):
First-line single-agent chemotherapy achieves cure rates of 98–100% in low-risk GTN.
• Methotrexate + Folinic Acid Rescue (MTX/FA): 8-day alternating regimen (MTX 1 mg/kg IM on days 1, 3, 5, 7 + folinic acid 0.1 mg/kg IM on days 2, 4, 6, 8, repeated every 14 days) — preferred first-line for most low-risk cases. Requires renal function monitoring.
• Actinomycin-D (Act-D): 1.25 mg/m² IV pulse every 2 weeks — preferred when MTX is contraindicated (renal impairment, hepatic dysfunction, or pleural/peritoneal effusions that trap MTX). Act-D has a higher complete remission rate in some trials and is commonly used as second-line after MTX failure in low-risk GTN.
• Treatment continues until β-hCG normalizes, then for a minimum of 3 additional consolidation cycles.
STEP 4 — CHEMOTHERAPY FOR HIGH-RISK GTN (FIGO SCORE ≥7 OR CHORIOCARCINOMA WITH METASTASES):
• EMA-CO Regimen (Etoposide, Methotrexate, Actinomycin-D / Cyclophosphamide, Vincristine): The international gold-standard for high-risk GTN, delivering complete remission in 78–94% of cases. Administered in alternating weekly cycles requiring inpatient infusion days and close hematologic monitoring.
• EMA-EP (Etoposide, Methotrexate, Actinomycin-D / Etoposide, Cisplatin): Reserved for EMA-CO-resistant or relapsed high-risk GTN. Higher toxicity profile; administered at specialized trophoblastic disease units.
• BEP (Bleomycin, Etoposide, Cisplatin): Considered for PSTT and ETT, which are characteristically resistant to MTX-based regimens.
• Targeted Therapy & Immunotherapy (Emerging): For ultra-refractory GTN, PD-L1 inhibitors (Pembrolizumab, Avelumab) have shown striking response rates in case series, as trophoblastic tumors overexpress PD-L1. Multi-tyrosine kinase inhibitors are under investigation. India's tier-1 oncology centers (e.g., Tata Memorial Hospital network affiliates, Apollo, Fortis Cancer Institute) and UAE's Cleveland Clinic Abu Dhabi and Mediclinic City Hospital oncology units have access to these agents within clinical protocols.
STEP 5 — SURGICAL MANAGEMENT OF COMPLICATIONS OR RESISTANT DISEASE:
• Hysterectomy for chemotherapy-resistant localized disease, uterine perforation, or PSTT/ETT (where surgery is the primary curative modality).
• Thoracoscopic resection of isolated pulmonary nodules in chemoresistant choriocarcinoma.
• Stereotactic Radiosurgery (SRS / Gamma Knife) for isolated brain metastases in high-risk GTN.
• Interventional radiology: Uterine artery embolization (UAE procedure) for life-threatening post-evacuation hemorrhage as a fertility-sparing alternative to hysterectomy.
Cost of Molar Pregnancy Treatment: India vs. UAE
The cost of molar pregnancy treatment varies substantially depending on the clinical complexity — a straightforward suction curettage with short surveillance is far less expensive than a full high-risk GTN chemotherapy course. Both India and the UAE offer internationally accredited care with transparent pricing, but India's cost advantage is significant, typically 50–65% lower than equivalent UAE care, making it the preferred destination for patients requiring extended chemotherapy cycles. The figures below represent total estimated patient-facing costs in USD, inclusive of the primary procedure, hospital stay, anesthesia, standard medications, and initial surveillance labs.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $800 – $7,000 | ~61% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $2,000 – $18,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PRE-TRAVEL PHASE (DAYS 1–7 BEFORE DEPARTURE):
• Obtain all current medical records: ultrasound reports, histopathology slides/blocks, β-hCG trend logs, prior treatment summaries.
• Upload documents to GAF Healthcare's secure patient portal for specialist pre-review within 24–48 hours.
• GAF Healthcare arranges a virtual consultation with the assigned gynecologic oncologist for case review, FIGO/WHO scoring, and treatment plan confirmation.
• Apply for Indian e-Medical Visa (processed within 3–5 business days) or confirm UAE visa-on-arrival / visit visa eligibility.
• Complete pre-procedure lab work either locally or at the hospital on Day 1 of arrival.
ARRIVAL & PRE-PROCEDURE (DAY 1–2 IN COUNTRY):
• GAF Healthcare team receives patient at the airport with dedicated wheelchair or transfer vehicle.
• Hospital admission and complete diagnostic workup: repeat serum β-hCG, CBC, LFT, RFT, TFT, blood group, pelvic ultrasound with Doppler, chest X-ray.
• Anesthesia assessment and pre-operative counseling.
• For GTN patients: staging CT scan and, if indicated, MRI brain.
• Signed informed consent covering evacuation procedure, anesthesia, blood transfusion possibility, and surveillance commitment.
PROCEDURE DAY (DAY 2–3):
• Suction curettage performed under general anesthesia in a fully equipped operating theater with intraoperative ultrasound guidance.
• Operative time: approximately 20–45 minutes for uncomplicated cases.
• All evacuated tissue sent for urgent histopathology with p57 immunohistochemistry and flow cytometry for definitive mole typing.
• Post-procedure recovery in monitored recovery room (2–4 hours), then transfer to inpatient room.
• First post-operative β-hCG drawn 24–48 hours post-evacuation to establish new baseline.
HOSPITAL DISCHARGE (DAY 3–5):
• Discharge criteria: hemodynamically stable, manageable vaginal bleeding, no signs of infection, initial β-hCG result reviewed.
• Discharge medications: anti-emetics, iron supplementation if anemic, contraceptive counseling (combined OCP or barrier method recommended for minimum 6 months to avoid confounding β-hCG surveillance).
POST-EVACUATION SURVEILLANCE IN COUNTRY (WEEKS 1–4):
• Weekly serum β-hCG at the hospital's outpatient trophoblastic disease clinic.
• If β-hCG normalizes within 8 weeks (typical for PHM) or 16 weeks (CHM): patient declared in complete remission and cleared for departure.
• If β-hCG plateaus or rises: repeat imaging, FIGO scoring, and initiation of chemotherapy as outpatient or short inpatient stay.
• Pathology report (usually available in 5–7 working days) reviewed with patient by gynecologic oncologist.
FIT-TO-FLY CLEARANCE & DEPARTURE (WEEKS 2–4 FOR UNCOMPLICATED MOLE; 8–12+ WEEKS IF CHEMOTHERAPY INITIATED):
• Written fit-to-fly clearance letter issued by treating specialist.
• GAF Healthcare coordinates continuation surveillance lab kits and referral letters for patient's home country gynecologist or oncologist.
• Airport transfer arranged; GAF case manager remains contactable for post-departure queries.
LONG-TERM FOLLOW-UP (MONTHS 1–12 AFTER DEPARTURE):
• PHM: Monthly β-hCG for 6 months after normalization.
• CHM: Monthly β-hCG for 12 months after normalization.
• GTN post-chemotherapy: β-hCG monthly for 12–18 months.
• Patients advised to avoid pregnancy during entire surveillance period.
• GAF Healthcare facilitates telemedicine follow-up with the treating specialist at 4-week intervals.
• Patients advised to report any irregular bleeding, respiratory symptoms, or neurological changes immediately, as these may signal late relapse.
Risks & Considerations
Molar pregnancy treatment carries procedure-specific, disease-specific, and surveillance-related risks that patients must understand before traveling. For suction curettage, risks include uterine perforation (reported in approximately 0.5–1% of cases, higher in large uteri), hemorrhage requiring transfusion (up to 5–10% of CHM cases due to hypervascular tissue), intrauterine adhesion formation (Asherman's syndrome, risk minimized by avoiding sharp curettage), and general anesthesia risks. Intraoperative dissemination of trophoblastic cells to the pulmonary vasculature — termed trophoblastic pulmonary embolism — can cause transient respiratory distress post-evacuation, typically self-limiting but requiring monitoring. Thyroid storm is a rare but life-threatening risk in patients with unrecognized molar hyperthyroidism who undergo anesthesia without pre-treatment. Regarding disease progression, approximately 15–20% of CHM and 1–5% of PHM cases will progress to GTN despite technically successful evacuation, making adherence to the post-evacuation β-hCG surveillance protocol the single most critical determinant of long-term outcome. Patients who interrupt surveillance prematurely face the risk of undetected malignant transformation, which, once metastatic, is substantially harder to cure. Chemotherapy for GTN carries regimen-specific toxicities: Methotrexate can cause mucositis, hepatotoxicity, and pneumonitis; Actinomycin-D causes myelosuppression and severe nausea; EMA-CO carries risks of peripheral neuropathy (vincristine), myelosuppression, alopecia, and secondary malignancy risk from etoposide with prolonged use. Fertility is generally preserved following molar pregnancy and GTN chemotherapy — studies confirm no increase in miscarriage, congenital abnormality, or preterm delivery in subsequent pregnancies — but patients are strongly advised to defer conception until the full surveillance period is complete (minimum 6–12 months after β-hCG normalization). Patients traveling internationally must maintain uninterrupted access to a laboratory capable of quantitative serum β-hCG testing throughout the follow-up period; GAF Healthcare actively coordinates this handoff to ensure no surveillance gap during or after the return journey.
Top Hospitals for Molar Pregnancy Treatment
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Manipal Hospitals Dwarka
New Delhi, India
Burjeel Hospital for Advanced Surgery Dubai
Dubai, UAE
Kings College Hospital Dubai
Dubai, UAE
Aster Hospital Dubai
Dubai, UAE
Top Doctors for Molar Pregnancy Treatment
Internationally trained specialists in Gynecology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Sarada Vani N
MBBS, DNB (Obstetrics & Gynecology), FFM (Fellowship in Fetal Medicine), Fellowship in Fetal Ultrasound, Fellowship in Fetal Cardiac Scanning, Fellowship in Medical Genetics, Fellowship in Cosmetic Gynaecology
Gynecologist & High-Risk Pregnancy Specialist
Yashoda Hospitals, Somajiguda, Hyderabad, India
23+ Yearsof experience
Dr. Sarada Vani N is a Senior Consultant in Obstetrics and Gynecology at Yashoda Hospitals, Somajiguda, Hyderabad, with more than 23 years of hands-on clinical experience. She is widely recognized for her expertise in high-risk pregnancies, minimally invasive gynecological surgery — including laparoscopic and robotic procedures — and comprehensive infertility care. Patients and colleagues alike describe her as a physician who combines deep clinical skill… Read more
Dr. Tarang Preet Kaur
MBBS, MS, MRCOG, MCh, Fellowship in Urogynaecology, Fellowship in Cosmetic Gynaecology
Urogynaecologist
Max Super Speciality Hospital, Saket, New Delhi, India
11+ Yearsof experience
Dr. Tarang Preet Kaur is a Consultant in Urogynaecology with over 11 years of clinical experience, currently practicing at Max Super Speciality Hospital, Saket in New Delhi. She holds an MCh in Urogynaecology from Edge Hill University, United Kingdom (2024), the MRCOG from the Royal College of Obstetricians & Gynaecologists, and an MS in Obstetrics & Gynaecology from Maulana Azad Medical College, Delhi. Her dual qualification across India and the UK… Read more
Dr. Amrinder Kaur Bajaj
MBBS, MD — Obstetrics & Gynaecology (Gold Medalist), Senior Residency — Obstetrics & Gynaecology, FRSH — Fellow of the Royal Society of Health, FIAMS — Fellow of the Indian Association of Medical Specialists
Obstetrician & Gynaecologist
Fortis Hospital, Gurgaon, Gurgaon, India
42+ Yearsof experience
Dr. Amrinder Kaur Bajaj is one of Delhi-NCR's most experienced gynaecologists, with over four decades spent caring for women at every stage of life. She currently practises as a Consultant in Obstetrics & Gynaecology at Fortis Hospital, Gurgaon, where she brings together deep clinical knowledge and a quietly reassuring bedside manner that patients — and their families — find genuinely comforting. Her academic journey set a high bar early on. She completed… Read more
Dr. Anuradha Khurana
MBBS, DGO (Diploma in Obstetrics & Gynaecology), PG in High Risk Pregnancy and Infertility
Gynecologist & Obstetrics Specialist
Artemis Hospital, New Delhi, India
20+ Yearsof experience
Dr. Anuradha Khurana is a Senior Consultant in Obstetrics and Gynecology at Artemis Hospital, Delhi, with over two decades of hands-on experience in women's health. She is particularly well regarded for her work in high-risk pregnancy management, uterine conditions like fibroids and endometriosis, and complex gynecological surgeries. Patients and families consistently describe her as someone who takes the time to truly listen — and to explain things in a… Read more
Dr. Aswari Kesari Kapoor
MBBS, DGO (Diploma in Gynaecology & Obstetrics), CPS (College of Physicians and Surgeons), DNB (Diplomate of National Board) — Obstetrics & Gynaecology
Obstetrician & Gynecologist
Indraprastha Apollo Hospital, New Delhi, India
23+ Yearsof experience
Dr. Aswari Kesari Kapoor is a seasoned Obstetrician and Gynecologist with over 23 years of hands-on clinical experience. She practices at Indraprastha Apollo Hospital in New Delhi — one of India's most respected multi-specialty institutions. Over the course of her career, she has built a strong reputation for managing complex gynecological conditions alongside high-risk pregnancies, all with a calm and reassuring bedside manner that patients consistently… Read more
Frequently Asked Questions — Molar Pregnancy Treatment
The cost of molar pregnancy treatment depends significantly on the clinical stage. For a straightforward diagnosis requiring suction curettage, a 1–2 day hospital stay, anesthesia, histopathology, and initial β-hCG surveillance, costs in India typically range from USD 800 to USD 3,000 at NABH- and JCI-accredited hospitals — among the lowest anywhere for equivalent specialist care. If post-evacuation monitoring reveals progression to gestational trophoblastic neoplasia (GTN) requiring chemotherapy (e.g., single-agent Methotrexate/Folinic Acid for low-risk GTN, or EMA-CO for high-risk GTN), total treatment costs in India may rise to USD 4,000–7,000 for a complete low-risk course, covering all chemotherapy cycles, blood monitoring, and outpatient visits. In the UAE (Dubai or Abu Dhabi), the equivalent suction curettage and initial care costs USD 2,000–5,000 at JCI- and DHA-accredited facilities, with a full GTN chemotherapy course reaching USD 8,000–18,000, reflecting the UAE's higher operational costs and premium hospital infrastructure. India is therefore approximately 50–65% more cost-effective than the UAE for this treatment. Both destinations include surgery, anesthesia, hospital accommodation, standard medications, and pathology in their package pricing when arranged through GAF Healthcare. Neither estimate includes international flights, personal accommodation, or companion expenses, which GAF Healthcare helps minimize through partner hotel rates.
The minimum safe in-country stay depends entirely on whether the molar pregnancy resolves without complication or progresses to gestational trophoblastic neoplasia (GTN). For an uncomplicated hydatidiform mole treated with suction curettage where β-hCG begins falling appropriately, most patients can be cleared to fly home within 2–4 weeks. During this period, the team confirms hemodynamic stability post-procedure, reviews histopathology results (usually available in 5–7 working days), monitors the initial post-evacuation β-hCG trend, and issues a formal fit-to-fly letter from the gynecologic oncologist. Patients are advised that flying too early — before a confirmed declining β-hCG trend — risks missing early signs of GTN transformation, which is why GAF Healthcare structures in-country stays around these clinical checkpoints rather than fixed calendar dates. If β-hCG plateaus or rises during the surveillance window, indicating GTN, treatment with chemotherapy is initiated and the required in-country stay extends to 8–12 weeks or longer, depending on the number of chemotherapy cycles needed and the speed of β-hCG normalization. Patients undergoing high-risk GTN treatment with multi-agent EMA-CO regimens should plan for 10–16 weeks of in-country stay. Post-departure, patients must continue serial β-hCG monitoring at a qualified laboratory in their home country for 6–18 months; GAF Healthcare coordinates the lab referral and telemedicine oversight throughout this period.
The prognosis for molar pregnancy is exceptionally favorable when detected early and managed at a specialist center with a formal trophoblastic disease surveillance program. For complete hydatidiform mole (CHM) treated with suction curettage and followed up with serial β-hCG monitoring, approximately 80–85% of patients achieve permanent remission with the evacuation procedure alone. The remaining 15–20% who develop post-molar GTN are treated with chemotherapy and achieve a cure rate of 98–100% with single-agent Methotrexate or Actinomycin-D for low-risk GTN (FIGO/WHO score 0–6). For partial hydatidiform mole (PHM), fewer than 5% progress to GTN, and virtually all are cured with single-agent chemotherapy. Even for high-risk GTN (FIGO score ≥7), including metastatic choriocarcinoma, the EMA-CO chemotherapy regimen achieves complete remission in 78–94% of patients, with salvage regimens (EMA-EP, BEP, or immunotherapy with Pembrolizumab) rescuing the majority of initially resistant cases. Overall, gestational trophoblastic disease — including its most aggressive form, choriocarcinoma — has the highest cure rate of any gynecologic malignancy, often exceeding 95% across all stages when managed at a trophoblastic disease center. India's premier oncology hospitals (with gynecologic oncology units running formal GTD registers) and the UAE's JCI-accredited cancer centers achieve outcomes consistent with international benchmarks. Critically, the success rate is directly tied to uninterrupted β-hCG surveillance; patients who complete the full follow-up protocol have near-universal cure rates. GAF Healthcare specifically supports surveillance continuity as a core service to protect this outcome.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare manages the complete non-medical infrastructure for international patients, ensuring that treatment logistics are as seamless as the clinical care itself.
INDIA — VISA & ENTRY: GAF Healthcare's visa coordination team assists patients in applying for the Indian e-Medical Visa online, which covers the patient and up to two accompanying attendants (e-Medical Attendant Visa). Processing typically takes 3–5 business days. The visa permits multiple entries and stays of up to 60 days per visit, with two further extensions available — ideal for patients undergoing extended β-hCG surveillance or multi-cycle chemotherapy.
UAE — VISA & ENTRY: Most international patients from Europe, North America, GCC countries, and a growing list of Asian nations receive a visa-on-arrival or a free 30–90 day visit visa upon landing in Dubai or Abu Dhabi. GAF Healthcare pre-confirms visa eligibility for each patient's passport nationality and assists with a formal medical visa or visa extension application when treatment duration exceeds standard tourist stay permissions. DHA (Dubai Health Authority) and DOH (Abu Dhabi Department of Health) facilities are accessible under these arrangements.
AIRPORT TRANSFERS: Dedicated GAF Healthcare ground coordinators meet all incoming patients and attendants at the arrival terminal — holding a named board — and arrange direct, air-conditioned transfer to the hospital or partner accommodation. Return airport drop-off is scheduled in coordination with the fit-to-fly clearance date.
DEDICATED PATIENT COORDINATORS & TRANSLATORS: Each patient is assigned a primary GAF Healthcare case manager fluent in the patient's language (available in English, Arabic, Russian, French, Hindi, and other major languages). The case manager accompanies the patient to key appointments, translates all verbal consultations on request, and provides written translations of discharge summaries and surveillance instructions. A 24/7 emergency helpline is available throughout the patient's stay.
ACCOMMODATION FOR ATTENDANTS: GAF Healthcare has negotiated rates at partner hotels and serviced apartments within 500 meters to 2 km of all affiliated hospitals in Mumbai, Delhi, Chennai, Hyderabad, Dubai, and Abu Dhabi. Attendant accommodation ranges from comfortable budget options to premium serviced apartments, all with in-room meal delivery and flexible check-out aligned to the patient's discharge date. For patients admitted for extended chemotherapy courses, long-stay apartment options with kitchenette facilities are available.
TELEMEDICINE & POST-DEPARTURE SUPPORT: Following discharge, GAF Healthcare schedules monthly telemedicine follow-up calls between the patient and the treating gynecologic oncologist for the duration of the surveillance period. β-hCG results from the patient's home country lab are shared via the GAF secure portal for remote review, and any concerning trend prompts immediate escalation guidance.